| Oct 28 |
This Johnson & Johnson Insider Reduced Their Stake By 37%
|
| Oct 28 |
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
|
| Oct 26 |
3 Dividend Growth Stocks You Can Buy and Hold Forever
|
| Oct 25 |
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
|
| Oct 25 |
J&J reports positive data for Tremfya in low body surface area psoriasis
|
| Oct 25 |
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
|
| Oct 25 |
Is Kenvue Stock a Buy Now?
|
| Oct 25 |
J&J’s comeback kid Spravato heads for blockbuster status
|
| Oct 24 |
Johnson & Johnson (JNJ): Legal Challenges Over Talc Products Impact Dow Performance
|
| Oct 24 |
Johnson & Johnson Investing $2B to Build Pharma Factory in North Carolina
|
